The amazing discovery under the authorship of Professor Chenfang Dong from the Zhejiang University School of Medicine in Hangzhou, China revealed that the widely used osteoporosis drug named zoledronic acid, inhibits UGT8 activity directly, which led to the prevention of basal-like breast cancer.
A research team led by Dr. Beatrice Nardone, research assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discovered that daily consumption of aspirin could significantly increase the risk for melanoma (skin cancer) in men, compared to women.
The annual meeting of the American Urological Association had Sesen Bio present its three-month data for its bladder cancer treatment Vicinium. This was Sesen Bio’s first readout following its name change from Eleven Biotherapeutics.
A research team at the University of Michigan were developing a pill which shows the presence of tumors when exposed to infrared light, and their concept worked well in mice.
More than one-quarter of the world’s population were constantly getting affected with the one of the world’s oldest and deadliest disease named Tuberculosis (TB). In spite of 6-9 months antibiotic therapy, it’s very difficult to treat tuberculosis. That’s why researchers throughout the world were trying to find the faster ways of cure.
Liver cancer is the second most common cancer with a high mortality rate worldwide. According to WHO, liver cancer is the fifth most common cancer in men and seventh most common cancer in women. Treatment could be possible only if diagnosed at an early stage. Hence research studies were conducted worldwide to find the most accurate diagnostic tool to detect liver cancer.
Researchers at the Perelman School of Medicine and the Abramson Cancer Center, at the University of Pennsylvania, developed the vaccine using dendritic cells (DCs) derived from each patient's own peripheral blood mononuclear cells. These dendritic cells were then exposed to the patient's tumor cells, activated with interferon gamma, and injected into the patient's lymph nodes.
With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
Expansion Includes the Joint Development of Moderna’s KRAS Oncogene Program and Other Potential mRNA Cancer Vaccines; Merck to Make Equity Investment in Moderna
First Filing Acceptance for an Anti-PD-1 Therapy in Cervical Cancer
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.